Recent Updates
Recently added Catalysts
LXEO Positive Sentiment Score: 70/100

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Tuesday, May 7, 2024 1 min read
Key Takeaway: Lexeo Therapeutics announced its participation in three upcoming investor conferences scheduled for May 2024. The events include the Citizens JMP Life Sciences Conference, the RBC Capital Markets Global Healthcare Conference, and the Bank of America Securities Health Care Conference. The participation showcases the company's focus on advancing treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. Live webcasts of the presentations will be available on their website, emphasizing their commitment to transparency and engagement with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple prestigious investor conferences highlights credibility.
  • Focus on genetically defined cardiovascular diseases and Alzheimer’s adds relevance.
  • Use of early proof-of-concept data demonstrates innovation in treatment development.

Full Press Release Details

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences:
The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ET
RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ET
Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT
The events will be webcast live under the News & Events tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.
About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.
janine.bogris@inizioevoke.com
stephen@gilmartinir.com

Frequently Asked Questions

When is the Citizens JMP Life Sciences Conference?

The Citizens JMP Life Sciences Conference is on May 13, 2024, at 9:00 AM ET.

What type of company is Lexeo Therapeutics?

Lexeo Therapeutics is a clinical stage genetic medicine company focused on cardiovascular diseases.

When will the RBC Capital Markets Conference take place?

The RBC Capital Markets 2024 Global Healthcare Conference is on May 14, 2024, at 11:00 AM ET.

Is there a way to watch the investor conferences?

Yes, the events will be webcast live on the Investors section of Lexeo's website.

What diseases does Lexeo Therapeutics target?

Lexeo Therapeutics targets genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s.

Tags: LXEO Viatris Investor Conferences Healthcare Lexeo Therapeutics investor conferences Alzheimer's disease cardiovascular diseases
Last updated: May 7, 2024